NEUROENDOCRINE CARCINOMA

This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…

This study tests an experimental drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have DLL3 protein. The goal is to find the safest dose and see if it helps shrink tumors. About 232 adults will take p…

This study tests whether combining two immunotherapy drugs, atezolizumab and bevacizumab, can shrink or control rare solid tumors that are hard to treat. About 133 adults with cancers like rare appendix, anal, cervical, penile, vulvar, neuroendocrine, Merkel cell, nasopharyngeal,…

This study tests a cancer-killing virus (VSV-IFNβ-NIS) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective virus …

This study tests an experimental oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants take the drug by mouth and are monitored…

This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and temozolomide (a chemotherapy that kills cancer cells)—in people with advanced small-cell lung cancer or neuroendocrine tumors that have come back or stopped res…

This study tests whether combining two drugs—niraparib (which blocks cancer cells from repairing themselves) and dostarlimab (which helps the immune system attack cancer)—can control small cell lung cancer and other high-grade neuroendocrine carcinomas. About 48 adults whose canc…

This study is a registry for people with neuroendocrine tumors (NETs), a rare type of cancer. Researchers will collect medical data and blood samples from 400 participants to study how well certain blood tests can detect tumor activity, recurrence, and treatment response. The goa…

This study follows over 2500 adults with neuroendocrine tumors (NETs) to learn how symptoms affect their lives and how doctors choose treatments. Participants fill out surveys about quality of life and care experiences over 18 months. The goal is to find the best ways to sequence…